EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genomic determinants and an exploratory prognostic model for immunotherapy outcomes in recurrent or metastatic cervical cancer

Lingling Gu, Biqing Zhu, Cuicui Liu, Xiaoying Wu, Yaru Zhang, Jiani Yin, Fufeng Wang, Tingting Hu, Yaqin Wu iD

The Oncologist · 06.06.2026 · 31 (7)

DOI: 10.1093/oncolo/oyag236 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 22.06.2026. Verfasst von Lingling Gu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Image Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical …. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Immunotherapy, Neoplasm Recurrence, Local, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Jiangsu Province Maternal and Child Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) improve outcomes in recurrent or metastatic cervical cancer, but responses are heterogeneous and biomarkers beyond programmed death-ligand 1 (PD-L1) are limited. Materials and Methods Targeted sequencing of 437 cancer-related genes was performed in 42 patients receiving ICI-based therapy. Genomic correlates of progression-free survival (PFS) were evaluated, and an exploratory prognostic model was developed using least absolute shrinkage and selection operator regression and multivariable Cox regression. The Cancer Genome Atlas (TCGA) cohort was used for transcriptomic analysis.

Results

The cohort included 42 patients, with a median age of 51 years; 85.7% were human papillomavirus-positive, 90.5% had squamous cell carcinoma, and 54.8% had a programmed death-ligand 1 combined positive score (PD-L1 CPS) ≥5. Frequent alterations included PIK3CA (57.1%), FBXW7 (21.4%), TERT (21.4%), BAP1 (19.0%), and EP300 (16.7%). Tumor mutational burden-associated mutations in PIK3CA, EP300, CREBBP, and TERT were associated with prolonged PFS (P < .001), whereas PD-L1–associated mutations showed numerically longer PFS (P = .170). EP300 (P = .007), PIK3CA (P < .01), and homologous recombination repair pathway alterations (P = .016) were associated with favorable PFS, whereas KEAP1 (P < .01) and TP53 (P = .010) mutations were associated with shorter PFS. A five-feature genomic model stratified patients into high- and low-risk groups (P < .001, 1-year AUC = .889). In the exploratory cohort, high-risk patients showed numerically shorter PFS (P = .060). In TCGA samples, high-risk tumors showed enrichment of angiogenesis, epithelial-mesenchymal transition, hypoxia, inflammatory response, and tumor necrosis factor-α/nuclear factor-κB signaling.

Conclusion

Specific genomic alterations may help stratify immunotherapy outcomes in recurrent or metastatic cervical cancer. The proposed genomic risk model remains exploratory and requires validation in larger, independent cervical cancer cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsImmunotherapyNeoplasm Recurrence, LocalBiomarkers, TumorImmune Checkpoint InhibitorsHumansFemalePrognosisMiddle AgedGenomicsAdultAged

Stichwörter der Autor:innen

biomarkerscervical cancergenomicsimmunotherapyprogression-free survival

Substanzen

Biomarkers, TumorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Image Center, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210000, China.
  • Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210000, China.
  • Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing 210032, China.
  • Department of Nursing, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210000, China.

ORCID-Profile: Yaqin Wu

Förderung

  • National Natural Science Foundation of China
  • Jiangsu Province Maternal and Child Health Research

Zitieren

APA

Gu, L., Zhu, B., Liu, C., Wu, X., Zhang, Y., Yin, J., Wang, F., Hu, T., & Wu, Y. (2026). Genomic determinants and an exploratory prognostic model for immunotherapy outcomes in recurrent or metastatic cervical cancer. The Oncologist, 31(7). https://doi.org/10.1093/oncolo/oyag236

Vancouver

Gu L, Zhu B, Liu C, Wu X, Zhang Y, Yin J, et al. Genomic determinants and an exploratory prognostic model for immunotherapy outcomes in recurrent or metastatic cervical cancer. The Oncologist. 2026;31(7). doi:10.1093/oncolo/oyag236

BibTeX
@article{Gu2026,
  author = {Gu, Lingling and Zhu, Biqing and Liu, Cuicui and Wu, Xiaoying and Zhang, Yaru and Yin, Jiani and Wang, Fufeng and Hu, Tingting and Wu, Yaqin},
  title = {Genomic determinants and an exploratory prognostic model for immunotherapy outcomes in recurrent or metastatic cervical cancer},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {7},
  doi = {10.1093/oncolo/oyag236}
}
Kostenlos starten →